Discovery of a new anti-γc antibody in clinical development for the treatment of autoimmune diseases
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkae020 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Chin Wai Hui und 5 weiteren Autor:innen. Beteiligte Einrichtung: SinoMab BioScience Limited, Pak Shek Kok, New Territories, Hong Kong, China. Hauptthemen laut MEDLINE: Autoimmune Diseases, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 107 Literaturangaben. Gefördert von: SinoMab BioScience Limited.
Abstract (Originalsprache)
Autoimmune disease refers to a condition when the immune system anomalously attacks its own body and healthy cells. Although the exact causes of autoimmune diseases are unknown, it is recognized that excessive or aberrant cytokine responses contribute significantly to the development of autoimmunity. Among them, the common gamma c chain (γc) cytokines driven signaling cascade plays an indispensable role in driving pathogenic immune responses in patients with autoimmune diseases. Thus, we hypothesize that the development of an antibody targeting γc receptor could serve as a potential approach for treating autoimmune diseases and fulfil the unmet medical needs in this area. Here, we demonstrate that a humanized anti-γc antibody, hC2, could show high binding affinity to the human γc receptor and suppress 6 γc cytokines (interleukin [IL]-2, IL-4, IL-7, IL-9, IL-15 and IL-21)-driven STAT phosphorylation, leading to inhibition of autoimmunity and activation in B, T, and natural killer cell lines. Similar inhibitory effects were observed in the human peripheral blood mononuclear cell culture. Moreover, administration of hC2 could reduce expansion and tissue infiltration of T helper and cytotoxic T cells, leading to attenuation of damages to skin, liver, and kidney in the humanized xenograft mouse model. The current study demonstrates the potential of γc blockades for the treatment of T cell–mediated autoimmune diseases and chronic graft-versus-host disease. Anti-γc antibody hC2 might offer a more efficacious therapy compared with antibodies targeting a single γc cytokine and safer therapy than JAK inhibitors to fulfill the unmet medical needs in the autoimmune diseases in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SinoMab BioScience Limited, Pak Shek Kok, New Territories, Hong Kong, China.
ORCID-Profile: Chin Wai Hui, Wai Chung Wu
Förderung
- SinoMab BioScience Limited
Zitieren
APA
Hui, C. W., Wu, W. C., Tong, T. K., Shiu, C., Ng, H. L., & Leung, S. O. (2025). Discovery of a new anti-γc antibody in clinical development for the treatment of autoimmune diseases. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkae020
Vancouver
Hui CW, Wu WC, Tong TK, Shiu C, Ng HL, Leung SO. Discovery of a new anti-γc antibody in clinical development for the treatment of autoimmune diseases. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkae020
BibTeX
@article{Hui2025,
author = {Hui, Chin Wai and Wu, Wai Chung and Tong, Tak Keung and Shiu, Carol and Ng, Hoi Lam and Leung, Shui On},
title = {Discovery of a new anti-γc antibody in clinical development for the treatment of autoimmune diseases},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkae020}
}
EUVIMED